IFIH1 and COVID-19: While patients with stabilized disease receiving immunosuppressive therapies-such as JAK inhibitors-may exhibit relative resilience to severe COVID-19, SARS-CoV-2 infection remains a significant threat for patients with new-onset, active, or uncontrolled anti-MDA5+ DM.